January 18th 2021, 4:00pm
In an interview, Dr. Matthew Davids of the Dana-Farber Cancer Institute discusses the future of CAR T-Cell therapy in the treatment of younger patients with chronic lymphocytic leukemia.
January 15th 2021, 10:00pm
In a recent interview with CURE®, a medical oncologist from the Dana-Farber Cancer Institute discussed why it’s important for patients with CLL, regardless of their treatment plans, to keep up on vaccinations and maintain a regular cancer screening schedule.
January 14th 2021, 3:00pm
In a recent interview with CURE®, a medical oncologist from the Dana-Farber Cancer Institute in Boston discussed how the addition of Copiktra to a three-drug chemotherapy combination improved outcomes in patients with CLL, with more than half achieving complete remission.
December 31st 2020, 4:00pm
In this episode of the “CURE Talks Cancer” podcast, we spoke with Mark Hoffman, a patient with chronic lymphocytic leukemia, about his diagnosis and treatment journey.
December 14th 2020, 4:00pm
More than half of the patients (66.7%) in the Venclexta and Rituxan arm who went on to receive subsequent Venclexta-based treatments experienced a partial response or partial nodal response to the therapy.
December 14th 2020, 2:00pm
Among 27 patients with relapsed/refractory chronic lymphocytic leukemia patients who completed all 12 cycles of the triplet therapy, 100% of patients had a complete or partial response to the treatment—with 41% achieving a complete response.
December 9th 2020, 2:00pm
The combination of ublituximab and umbralisib, two novel compounds, was able to safely prolong progression-free survival with low rates of toxicities in patients with chronic lymphocytic leukemia compared with standard of care chemoimmunotherapy regardless of prior treatment.
December 8th 2020, 10:00pm
At a median follow-up of 25.9 months, 17% of the patient population who received Calquence monotherapy experienced a cardiac toxicity of any severity, which led to treatment discontinuation in only seven patients.
December 8th 2020, 7:00pm
The early study of the investigational CAR-T cell therapy lisocabtagene maraleucel shows how patients with relapsed/refractory CLL/SLL may have a viable new treatment option.
December 7th 2020, 8:00pm
Imbruvica treatment in patients with chronic lymphocytic leukemia whose disease expressed a certain mutation elicited sustained efficacy over a median follow-up of four years, according to data from a long-term analysis.
5 Recent COVID-19 News and Updates That Patients With Cancer May Have Missed
FDA Approves Cabometyx-Opdivo For Metastatic RCC Treatment
Novel Therapy Granted Priority Review By FDA for Treatment of Anal Cancer Subset
COVID-19 'Retired' Me, But Now I Can Reach For My Life Goals
